<em>m/z</em> 429.1) of the eluting components. A search of potential molecular structures in the <em>Dictionary of Natural Products</em> (CRC Press, v17.1) for <em>Cacospongia</em> spp. as the biological source and limited by exact molecular masses of 428.0&#x02013;428.5 and 386.0&#x02013;386.5 mmu returned seven scalarane-type sesterterpenes, neither of which possessed reported cation channel inhibitory activity. As a prioritized sample, subsequent scaled-up isolation of the suspected active compounds was carried out.</p></div><div id="S14" class="sec"><h3 id="S14title">Isolation of Scalaradial and 12-Deacetylscalaradial.</h3><p id="P27" class="p p-first-last">Freeze-dried sponge material was extracted with methanol, and the residue was repeatedly chromatographed to &#x0003e;95% purity by reversed-phase HPLC (Agilent 1100; Phenomenex Luna C18(2) column, 10 <em>&#x003bc;</em>m, 10 &#x000d7; 250 mm; mobile phase: acetonitrile/10 mM aqueous NH<sub>4</sub>OAc, 89:11; flow rate: 3.8 mL/min; UV detection, 222&#x02013;238 nm). Scalaradial and 12-deacetylscalaradial were identified by comparison of <sup>1</sup>H and <sup>13</sup>C NMR, MS, and polarimetry data with literature values.<sup><a href="#R65" rid="R65" class=" bibr popnode">65</a>,<a href="#R66" rid="R66" class=" bibr popnode">66</a></sup> Prior to bioassay, the purity of scalaradial and 12-deacetylscalaradial were determined by analytical HPLC by UV detection [Agilent 1100; Phenomenex Luna C18(2) column, 5 <em>&#x003bc;</em>m, 2.0 &#x000d7; 250 mm; mobile phase: acetonitrile/10 mM aqueous NH<sub>4</sub>OAc,50:50 for 2 min, then linear gradient from 50:50 to 100:0 over 30 min; flow rate: 0.20 mL/min; UV detection, 222&#x02013;238 nm].</p></div><div id="S15" class="sec"><h3 id="S15title">Cell Culture.</h3><p id="P28" class="p p-first">Wild-type (nontransfected) human embryonic kidney (HEK293) cells and tetracycline-inducible HEK293 cells stably transfected with either a FLAG-human TRPM2/pcDNA4/TO construct<sup><a href="#R3" rid="R3" class=" bibr popnode">3</a></sup> or a FLAG-murine TRPM7/pCDNA4/TO construct <sup><a href="#R24" rid="R24" class=" bibr popnode">24</a></sup> were cultured at 37 &#x000b0;C with 5% CO<sub>2</sub> in DMEM supplemented with 10% fetal bovine serum. For the TRPM2- and TRPM7-transfected cells, the medium was supplemented with blasticidin (5 <em>&#x003bc;</em>g/mL; Invitrogen) and zeocin (0.4 mg/mL; Invitrogen). TRPM2 and TRPM7 overexpression was induced by adding 1 <em>&#x003bc;</em>g/mL tetracycline to the media 5&#x02013;22 h before experiments.</p><p id="P29">For the electrophysiological analysis of CRAC-like currents, we used HEK293 cells stably transfected with an STIM1-pIRESneo vector construct (cell line kindly provided by D. L. Gill&#x02019;s lab),<sup><a href="#R67" rid="R67" class=" bibr popnode">67</a></sup> which, in addition, were transiently transfected with a CRACM1-pIRES2-EGFP vector construct.<sup><a href="#R68" rid="R68" class=" bibr popnode">68</a>,<a href="#R69" rid="R69" class=" bibr popnode">69</a></sup> Cells were cultured at 37 &#x000b0;C with 5% CO<sub>2</sub> in DMEM supplemented with 10% fetal bovine serum. CRAC recordings were performed 24&#x02013;48 h post-transfection, with cotransfected cells being identified by the fluorescence of EGFP.</p><p id="P30" class="p p-last">The rat insulinoma cell line (INS-1) was kept at 37 &#x000b0;C with 5% CO<sub>2</sub> in RPMI containing 10% fetal bovine serum.</p></div><div id="S16" class="sec"><h3 id="S16title">Calcium Imaging Assay for TRPM2 Inhibitors.</h3><p id="P31" class="p p-first-last">Changes in cytosolic [Ca<sup>2+</sup>] were monitored as changes in fluorescence using the Ca<sup>2+</sup>-indicator dye fura-2<sup><a href="#R70" rid="R70" class=" bibr popnode">70</a></sup> and a scanning plate reader (FlexStation, Molecular Devices). Data were collected and processed using SoftMax Pro software (v5.2, Molecular Devices). TRPM2-HEK293 cells were plated in poly-<span class="small-caps">l</span>-lysine-coated 96-well plates, and TRPM2 expression was induced 2&#x02013;3 h after plating by addition of 2&#x02013;10 <em>&#x003bc;</em>g/mL tetracycline. The culture medium was completely removed at 16&#x02013;20 h post induction and replaced with the fura-2 loading buffer: KRH buffer supplemented with 2 <em>&#x003bc;</em>M fura-2 acetoxymethyl ester (fura-2 AM; Calbiochem) and 0.1% Pluronic F-127. Following incubation (45 min at 37 &#x000b0;C) the loading buffer was removed, and the cells were washed once with KRH before the addition of assay buffer (KRH). The plates were then transferred to the prewarmed FlexStation (37 &#x000b0;C), which also contained a compound plate with separate wells containing the appropriate test substance solutions (i.e., vehicle, extracts/fractions of marine organisms, and compounds) or H<sub>2</sub>O<sub>2</sub> dissolved in KRH. Cells were initially incubated with the appropriate drugs or vehicle for ~20 min or as indicated prior to addition of a final 250&#x02013;1000 <em>&#x003bc;</em>M H<sub>2</sub>O<sub>2</sub>. In all assays performed, vehicle-receiving, induced cells served as positive control for the activation of a TRPM2-mediated Ca<sup>2+</sup> influx, while wells containing noninduced cells (receiving vehicle) periodically served as negative controls to define the baseline for the changes of cytosolic [Ca<sup>2+</sup>]. Intracellular [Ca<sup>2+</sup>] was monitored for up to ~2 min following compound/vehicle addition (or the entire compound/vehicle incubation time, if shorter) and for 2~3 min following H<sub>2</sub>O<sub>2</sub> addition as the fluorescence intensity was measured at 510 nm after excitation at 340 nm (Ca<sup>2+</sup>-bound fura-2). The change in relative fluorescence was used to monitor changes in intracellular [Ca<sup>2+</sup>].</p></div><div id="S17" class="sec"><h3 id="S17title">Electrophysiology.</h3><p id="P32" class="p p-first-last">Patch-clamp experiments were performed in the whole-cell configuration at 21&#x02013;25 &#x000b0;C. All data were acquired with PatchMaster (HEKA) software controlling an EPC-9 amplifier (HEKA, Lambrecht, Germany) and analyzed using FitMaster (HEKA) and Igor Pro (Wavemetrics). Voltage ramps of 50 ms spanning from &#x02212;100 to +100 mV were delivered from a holding potential of 0 mV at a rate of 0.5 Hz. Voltages were corrected for liquid junction potentials (10 mV). Currents were filtered at 2.9 kHz and digitized at 100 <em>&#x003bc;</em>s intervals. Capacitive currents were determined and corrected before each voltage ramp. For analysis, current amplitudes were extracted at &#x02212;80 mV, but for TRPM2 and TRPM7 currents were not corrected for the cell capacitance, and TRPM7 was assessed at +80 mV. Usual cell capacitance was 12&#x02013;20 pF for HEK293 cells and 7&#x02013;12 pF for INS cells. CRACM1/STIM1 currents were measured using a voltage ramp ranging from &#x02212;150 to +150 mV within 50 ms.</p></div><div id="S18" class="sec"><h3 id="S18title">Solutions and Chemicals.</h3><p id="P33" class="p p-first-last">For patch-clamp experiments cells were kept in standard external Ringer&#x02019;s solution (in mM): 140 NaCl, 2.8 KCl, 1.0 CaCl<sub>2</sub>, 2.0 MgCl<sub>2</sub>, 10 glucose, and 10 HEPES-NaOH (pH 7.2 adjusted with NaOH), 310 mOsm. Standard internal pipet-filling solutions contained (in mM) 140 Cs-glutamate for (INS-1 and Jurkat T cells), 140 K-glutamate (for HEK293 Flag-TRPM2 and Flag-TRPM7 expressing cells), 8.0 NaCl, 1.0 MgCl<sub>2</sub>, and 10 HEPES (pH 7.2 adjusted with CsOH/KOH). For recordings of TRPM2- and TRPV1-mediated currents, Ca<sup>2+</sup> was left unbuffered by leaving out Ca<sup>2+</sup> chelators. For TRPM2, ADPR was added to its final concentrations of 100 or 500 <em>&#x003bc;</em>M. For recordings of TRPM7-mediated currents, intracellular Ca<sup>2+</sup> was buffered with 10 mM BAPTA. Solutions for the recordings of CRAC currents were the following: standard external solution (in mM): 120 NaCl, 10 CsCl, 2.8 KCl, 2.0 MgCl<sub>2</sub>, 10 CaCl<sub>2</sub>, 10 TEA-Cl, 10 HEPES, and 10 glucose, pH was adjusted to 7.2 with NaOH, 300 mOsm. Internal solution was as follows (in mM): 120 Cs-glutamate, 20 Cs-BAPTA, 3.0 MgCl<sub>2</sub>, 10 HEPES, and 0.020 inositol 1,4,5-trisphosphate (IP<sub>3</sub>), pH was adjusted to 7.2 with CsOH, 300 mOsm. All reagents and drugs were purchased from Sigma-Aldrich except for Akt inhibitor VIII (Calbiochem, 1,3-dihydro-1-(1-((4-(6-phenyl-1<em>H</em>-imidazo [4,5-<em>g</em>]quinoxalin-7-yl)-phenyl)methyl)-4-piperidinyl)-2<em>H</em>-benzimidazol-2-one or synonym: Akti-1/2) and fura-2 AM. Scalaradial was isolated and purified as described above, reconstituted in methanol (2.0 mM), and diluted with KRH to a working solution of 200 <em>&#x003bc;</em>M.</p></div><div id="S19" class="sec sec-last"><h3 id="S19title">Statistical Analysis.</h3><p id="P34" class="p p-first">Patch-clamp data were acquired with PatchMaster software and exported to IGOR Pro (Wavemetrics). Current amplitudes were extracted from IGOR Pro and transferred to Excel (MS Office 2007), where all values for mean, standard deviation, and standard error of the mean were calculated. In some cases <em>p</em>-values based on unequal variances <em>t</em> test (unpaired, 2-tail) were calculated (Excel, TTEST function). Comparison of time course data was performed using one-way ANOVA with Tukey&#x02019;s multiple comparison test. Significance level was set at 0.05.</p><p id="P35" class="p p-last">Calcium imaging data were processed in SoftMax Pro. Maximum rate of Ca<sup>2+</sup> influx was determined for each test well by line fitting 5 points (spanning ~16 s) that give the largest slope (5-point &#x0201c;Vmax&#x0201d; reduction applied). Resulting slopes were normalized to vehicle control. Fifty-percent inhibitory concentration curves for patch-clamp and Ca<sup>2+</sup> imaging were fitted in IGOR Pro.</p></div></div><div id="S20" class="tsec sec"><h2 class="head no_bottom_margin" id="S20title">ACKNOWLEDGMENTS</h2><div class="sec"><p id="P36">This work was supported in part by grants from the Hawaii Community Foundation (Grant No. 20061480) (J.S.), NIH R01GM070634-04 (A.F.), NIH R01GM063954 (R.P.), and NIH P20GM103466 (F.D.H.). We thank B. Castillo, C. Kuo, J. Reinicke, J. Sahara, Tifanie Vansach, and S. Johne for excellent technical support. We thank I. Lange for critical feedback.</p></div></div><div id="idm140252741241472" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140252741241472title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN3"><p id="P41" class="p p-first-last">The authors declare no competing financial interest.</p></p></div></div><div id="idm140252794199952" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140252794199952title">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">(1) <span class="mixed-citation">Faouzi M; Penner R
